ES2496669T3 - Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen - Google Patents

Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen Download PDF

Info

Publication number
ES2496669T3
ES2496669T3 ES09712902.7T ES09712902T ES2496669T3 ES 2496669 T3 ES2496669 T3 ES 2496669T3 ES 09712902 T ES09712902 T ES 09712902T ES 2496669 T3 ES2496669 T3 ES 2496669T3
Authority
ES
Spain
Prior art keywords
benzophenantridine
formulations containing
antitumor agents
acid
alkaloids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09712902.7T
Other languages
English (en)
Inventor
Ezio Bombardelli
Gabriele Fontana
Paolo Morazzoni
Antonella Riva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Application granted granted Critical
Publication of ES2496669T3 publication Critical patent/ES2496669T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El uso de alcaloides de benzofenantridina o las sales de estos para la preparación de medicamentos para el tratamiento de tumores, en donde los alcaloides están en forma de sal con ácido luteico, con ácido hialurónico o con un ácido fosfatídico

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES09712902.7T 2008-02-22 2009-02-16 Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen Active ES2496669T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20080284 2008-02-22
IT000284A ITMI20080284A1 (it) 2008-02-22 2008-02-22 Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
PCT/EP2009/001079 WO2009103476A1 (en) 2008-02-22 2009-02-16 Antitumoral agents with a benzophenanthridine structure and formulations containing them

Publications (1)

Publication Number Publication Date
ES2496669T3 true ES2496669T3 (es) 2014-09-19

Family

ID=40291684

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09712902.7T Active ES2496669T3 (es) 2008-02-22 2009-02-16 Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen

Country Status (16)

Country Link
US (1) US8337903B2 (es)
EP (1) EP2242492B1 (es)
JP (1) JP5693970B2 (es)
KR (1) KR101633717B1 (es)
CN (1) CN101951907A (es)
AU (1) AU2009217020B2 (es)
CA (1) CA2716019C (es)
DK (1) DK2242492T3 (es)
ES (1) ES2496669T3 (es)
IL (1) IL207683A (es)
IT (1) ITMI20080284A1 (es)
PL (1) PL2242492T3 (es)
PT (1) PT2242492E (es)
RU (1) RU2492862C2 (es)
SI (1) SI2242492T1 (es)
WO (1) WO2009103476A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080038A1 (it) * 2008-01-11 2009-07-12 Indena Spa Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN102764259A (zh) * 2011-05-03 2012-11-07 中国科学院动物研究所 血根碱类化合物在制备防治癌症的药物中的用途和药物组合物
EP2759201B1 (en) 2012-04-03 2017-08-23 The Shizuoka Chamber of Commerce and Industry Composition for improving resistance to environmental stress of plant and method for improving resistance to environmental stress of plant
CN102887904B (zh) * 2012-10-10 2015-01-14 广西师范大学 2,3-二氧乙基-5-甲基-8,9-二甲氧基苯并菲啶衍生物及其制备方法和应用
KR102456075B1 (ko) 2015-10-15 2022-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함하는 유기 발광 소자
CN110339171A (zh) * 2018-04-03 2019-10-18 临沂大学 一种白屈菜红碱固体分散体
CN111467347A (zh) * 2020-04-30 2020-07-31 河北医科大学第二医院 苯并菲啶生物碱类化合物用于制备ano1 编码的钙激活氯离子通道阻断剂的用途
KR102893442B1 (ko) * 2022-12-23 2025-12-01 가톨릭대학교 산학협력단 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN118717764B (zh) * 2024-06-21 2025-01-24 中国人民解放军空军军医大学 白屈菜红碱、白屈菜碱联合血根碱在制备癌症治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
US4769452A (en) * 1986-02-07 1988-09-06 Vipont Laboratories, Inc. Production of purity benzo-c-phenanthridine alkaloid salts
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
GB9211659D0 (en) * 1992-06-02 1992-07-15 Indena Spa New alkaloid derivatives,their use and pharmaceutical formulations containing them
US6025365A (en) * 1997-03-25 2000-02-15 Arch Development Corp. Chelerythrine and radiation combined tumor therapy
JP2000109428A (ja) * 1998-10-05 2000-04-18 Taisho Pharmaceut Co Ltd 咽頭粘膜用組成物
CH695417A5 (de) * 2001-11-15 2006-05-15 Ddr Wassyl Nowicky Dipl Ing Verfahren zur Umsetzung von Alkaloiden.
EP1459753A1 (en) * 2003-03-18 2004-09-22 Nowicky, Wassyl, Dipl.-Ing. DDr. Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono

Also Published As

Publication number Publication date
CN101951907A (zh) 2011-01-19
EP2242492A1 (en) 2010-10-27
IL207683A (en) 2014-04-30
CA2716019C (en) 2016-07-05
US20100331525A1 (en) 2010-12-30
US8337903B2 (en) 2012-12-25
RU2010134570A (ru) 2012-02-27
EP2242492B1 (en) 2014-07-23
KR101633717B1 (ko) 2016-06-27
PL2242492T3 (pl) 2015-02-27
AU2009217020B2 (en) 2013-11-28
AU2009217020A1 (en) 2009-08-27
DK2242492T3 (da) 2014-09-15
KR20100119551A (ko) 2010-11-09
WO2009103476A8 (en) 2009-12-03
IL207683A0 (en) 2010-12-30
PT2242492E (pt) 2014-09-04
WO2009103476A1 (en) 2009-08-27
ITMI20080284A1 (it) 2009-08-23
CA2716019A1 (en) 2009-08-27
JP2011512370A (ja) 2011-04-21
SI2242492T1 (sl) 2014-10-30
JP5693970B2 (ja) 2015-04-01
RU2492862C2 (ru) 2013-09-20

Similar Documents

Publication Publication Date Title
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
CR11857A (es) Compuestos pirazolicos 436
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
CR20120605A (es) Formulación tópica para un inhibidor de jak
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
ECSP088296A (es) Compuestos terapéuticos
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
AR083268A1 (es) Conjugado de naloxol-peg cristalino
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
ES2531516T3 (es) Uso de escina
ES2482168T3 (es) Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
AR063027A1 (es) Derivados de sulfonamida
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos